All In Biotech

Drug Trial Radar · NCT03331302

Hyper Polarized Xenon-129 MRI vs Xenon-133 Scintigraphy

Last checked: Nov 19, 2026Latest source record: Nov 4, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Sep 1, 2018

Primary completion

Jun 30, 2020

Study completion Dec 31, 2020

Sponsor

Lead sponsor
University of VirginiaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 6, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Crossover
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Hyper polarized Xenon-129 MRI will be directly compared to a radioactive Xe-133 scintigraphy to detect defects in lung ventilation from airflow limitation. This study is conducted as a pilot study with intention to conduct a larger clinical trial.

Conditions

  • Chronic Obstructive Pulmonary Disease

Interventions

  • Hyperpolarized Xenon-129 MRI (Experimental)Drug

    MRI ventilation scan of the lung with inhaled contrast agent (hyperpolarized Xenon-129)

  • Radioactive Xenon-133 scintigraphy (Active Comparator)Drug

    Radioactive ventilation scintigraphy of the lung with inhaled radioactive contrast agent (Xenon-133)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Ventilation imaging resolution comparison between MRI and scintigraphyTime frame: 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Virginia Health System

    Charlottesville, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.